Premium
Tracking of epidermal growth factor receptor in cancer cells using nanodiamond
Author(s) -
Lin YuWei
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.925.8
Subject(s) - cetuximab , epidermal growth factor receptor , cancer cell , cancer research , monoclonal antibody , nanodiamond , colorectal cancer , cancer , epidermal growth factor , chemistry , antibody , receptor , medicine , immunology , biochemistry , organic chemistry , diamond
Nanodiamond (ND), a carbon‐based nanomaterial, has constituted a promising tool for bi‐imaging applications due to its excellent properties, including photostability, biocompatibility, and surface functionalization. Epidermal growth factor receptor (EGFR) is highly expressed in human cancer cells such as colorectal cancer (CRC). Cetuximab (Cet), a specific EGFR monoclonal antibody, has been approved for CRC therapy. Currently, nanoparticle‐antibody formulations display their ability to selectively bind on tumor cells through the ligand‐receptor interactions and increase the therapeutic efficacy. Here, we show the ND‐Cet complex that can be simply manipulated for tracking the EGFR in cancer cells. We demonstrated that ND‐Cet increased the uptake ability of drug complexes in the EGFR expressed cancer cells but not the EGFR absent cells. The fluorescence image of NDs can track the location of the binding of EGFR and Cet. We demonstrated a novel strategy using ND‐Cet to track the location of EGFR in cancer cells, which can be developed for the detection of specific cancer antigens.